Compare Deckers Outdoor Corp (DECK) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Deckers Outdoor Corp vs Cassava Sciences Inc — how do they compare? Deckers Outdoor Corp trades at $82.76 (market cap $11.24B), while Cassava Sciences Inc trades at $0.83 (market cap $39.40M). The key difference: Deckers Outdoor Corp is far larger — about 285.3× Cassava Sciences Inc's market cap, and Cassava Sciences Inc is more actively traded (759,018 versus 3,010,945). Which is the better fit depends on your goals — on Pluang, investors hold Deckers Outdoor Corp for 71 Days and Cassava Sciences Inc for 37 Days on average.
| DECK | FLNA | |
|---|---|---|
Market Cap | $11.24B | $39.40M |
Volume | 3,010,945 | 759,018 |
Sector | Consumer Cyclical | Health |
52-Week High | $120.94 | $4.64 |
52-Week Low | $77.51 | $0.68 |
Typical Hold Time | 71 Days | 37 Days |
Enterprise Value | $10.11B | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Deckers (DECK) trades at $82.15, up 2.2% with neutral technical signals. The company demonstrates strong fundamentals with consistent earnings beats, 19.4% net margin, and robust revenue growth from $3.2B in 2022 to $5.0B in 2025. Recent news highlights HOKA and UGG brand momentum driving investor optimism. Technical indicators show the stock trading near resistance at $82 with support at $79.
DECK presents compelling value with a P/E of 11.7x below industry averages and analyst consensus target of $117 suggesting 43% upside. Risks include competitive pressures in footwear and potential macroeconomic headwinds affecting consumer discretionary spending. The strong cash flow generation and brand strength support continued growth potential.
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Deckers Outdoor Corp
Deckers Outdoor Corp designs and sells casual and performance footwear, apparel, and accessories. Primary brands include UGG, Teva, and Sanuk. The company distributes Most of its products through its wholesale business, but it also has a substantial direct-to-consumer business with its company-owned retail stores and websites. Most sales are in the United States, although the company also has retail stores and distributors throughout Europe, Asia, Canada, and Latin America. Deckers sources its products from independent manufacturers primarily in Asia.
Read more on DECK →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
